Latest News

Date Title Topic
09 Feb 2017 Press Release: ESMO Announces New Award for Achievements in Immune-Oncology
09 Feb 2017 Media Alert: ESMO Summit Africa 2017
08 Feb 2017 Our Patient Guide in Breast Cancer Is Now Available Also in Polish
08 Feb 2017 Our Patient Guide on Ovarian Cancer is Now Available in Russian
07 Feb 2017 Now Available in Polish, the ESMO/ACF Patient Guide on Colorectal Cancer
07 Feb 2017 ESMO Preceptorship on Neuroendocrine Neoplasms
07 Feb 2017 Withdrawal of the Marketing Authorisation Application for Zioxtenzo (Pegfilgrastim) Palliative and supportive care
06 Feb 2017 EMA Recommends Granting a Marketing Authorisation for Hybrid Methotrexate Haematologic malignancies - Anticancer agents & Biologic therapy
03 Feb 2017 FDA Grants Accelerated Approval to Nivolumab for Treatment of Advanced Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
02 Feb 2017 ESMO advocates for Cancer Resolution at WHO Executive Board Meeting
02 Feb 2017 Council of Europe Data Protection Day Guidelines to Protect the People Behind Big Data Bioethics, legal and economic issues
01 Feb 2017 Nature Reviews Clinical Oncology – Year in Review Genitourinary cancers - Haematologic malignancies - Endocrine and neuroendocrine tumours - Sarcomas - Lung and other thoracic tumours - Head and neck cancers
31 Jan 2017 Withdrawal of the Application for a Change to the Marketing Authorisation for Denosumab Palliative and supportive care
30 Jan 2017 EMA Recommends Extension of Indications for Lenalidomide in Multiple Myeloma Haematologic malignancies - Anticancer agents & Biologic therapy
27 Jan 2017 NICE Issues Technology Appraisal Guidance for Ibrutinib for Previously Treated CLL and Untreated CLL with 17p Deletion or TP53 Mutation Haematologic malignancies - Anticancer agents & Biologic therapy